Hydroxyethyl Starch (130 kD) Inhibits Toll-Like Receptor 4 Signaling Pathways in Rat Lungs Challenged with Lipopolysaccharide

• DOI: 10.1213/ane.0b013e3182159c15
• Publication Date: 2011-03-19T06:45:38Z
• Authors: Jie Tian; Yunxia Wang; Zhengyu He; Yuan Gao; Joyce E. Rundhaug; Xiangrui Wang
• Keywords: Lipopolysaccharides; Male; Rats; 3. Good health; Hydroxyethyl Starch Derivatives; Rats, Sprague-Dawley; Toll-Like Receptor 4; Random Allocation; 03 medical and health sciences; 0302 clinical medicine; Sepsis; Animals; Lung; Signal Transduction

A number of studies have shown that hydroxyethyl starch (HES) solutions are able to down-regulate the expression of inflammatory mediators and inhibit neutrophil-mediated tissue injuries when they are used in patients with sepsis or other diseases with severe inflammatory responses. However, our knowledge about the underlying mechanisms is limited. Toll-like receptor 4 (TLR4) signaling has a pivotal role in inflammatory processes. In this study, we examined the possible involvement of TLR4 signaling in the antiinflammatory effects of HES.Male Sprague-Dawley rats were exposed to lipopolysaccharide (LPS) (10 mg/kg, IV) and received IV saline (30 mL/kg) or HES 130/0.4 (15 or 30 mL/kg). Six hours after LPS challenge, rats were killed and their lungs harvested. Lung injury was examined by hematoxylin and eosin staining. TLR4 mRNA expression, p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinases 1/2 MAPK activation, and activator protein 1 (AP-1) activity in the lungs were detected with quantitative polymerase chain reaction, Western blotting, and electrophoretic mobility shift assay, respectively.Compared with saline, HES profoundly attenuated the histological changes induced by LPS in the lungs at both dose levels. Molecular analysis showed that both 15 and 30 mL/kg HES significantly decreased TLR4 mRNA levels and inhibited activation of p38 MAPK and AP-1 in rats challenged with LPS, whereas activation of extracellular signal-regulated kinases 1/2 MAPK was not affected by either dose of HES.These findings indicate that the beneficial effects of HES 130/0.4 on inflammation are mediated at least in part by inhibiting the TLR4/p38 MAPK/AP-1 pathway in lungs from rats challenged with LPS.